# Index of Suspicion: Predictors of Tricuspid Regurgitation Progression and Follow-up Echo Imaging in An Artificial-intelligence Enhanced Study

OMAR KHALIQUE, MD, FACC, FASE, FSCCT, FSCMR, FSCAI

DIRECTOR, DIVISION OF CARDIOVASCULAR IMAGING

DIRECTOR, ADVANCED CARDIOVASCULAR IMAGING FELLOWSHIP

SAINT FRANCIS HOSPITAL AND CATHOLIC HEALTH SYSTEM OF LONG ISLAND

PROFESSOR OF CLINICAL CARDIOLOGY
NEW YORK INSTITUTE OF TECHNOLOGY

DIRECTOR, CARDIOVASCULAR IMAGING RESEARCH AND EDUCATION
DEMATTEIS CARDIOVASCULAR INSTITUTE

DIRECTOR, STRUCTURAL CT CORE LAB
CARDIOVASCULAR RESEARCH FOUNDATION









#### St. Francis Hospital & Heart Center

**1-732-352-1497** | Roslyn, NY 11576-1353

#29 in Cardiology & Heart Surgery Hospitals

### Background

- Tricuspid regurgitation (TR) is associated with negative outcomes.
- There are few data on factors influencing TR progression and patient follow-up after TR is discovered.

#### Methods

- ► A retrospective cohort study of patients with less than severe TR was conducted from August 2018 to December 2021 to identify predictors of
- 1) disease progression to severe TR, and
- 2) presence of follow up echo.
- Patients were followed up from their first (index) echo with TR up until June 2023. Data were collected using Tempus Next (Tempus Labs Inc, Chicago, IL).
- Demographic and Echo indices were parsed from the Echo report using natural language processing.
- Multivariate Cox proportional-hazards model examined the association between predictors and disease progression. Logistic regression examined predictors of undergoing a follow-up echo. Both analyses controlled for index disease severity.

#### Results

- ➤ 33,108 patients with TR (27,107 mild, 2,517 mild-moderate, 2,851 moderate, 633 moderate-severe) were included in the study (min / max / average observation times: 521 / 1,769 / 1,060 days).
- ► 10,696 (32%) had a follow up echo that allowed us to assess disease progression (average time to follow up 570 days; range: 31-1,743 days).
- ► 306 (2.9% of 10,696) eventually progressed to severe TR.

## Predictors of Disease Progression

Disease Progression: 306/10696 patients		N	Hazard ratio		р
TR Severity at index	mild	3915		Reference	
	mild-moderate	739	<b>⊢</b> ■→	2.32 (1.48, 3.64)	<0.001
	moderate	983	<b>H</b>	4.95 (3.43, 7.15)	<0.001
	moderate-severe	211	1	11.83 (7.59, 18.43)	<0.001
Gender	Male	3010	į.	Reference	
	Female	2838	i ·	1.59 (1.21, 2.09)	<0.001
Patient Admission Status	Outpatient	3057		Reference	
	Inpatient	2791	<b>=</b>	1.22 (0.93, 1.61)	0.152
Age (years)		5848	Ė	1.02 (1.01, 1.03)	0.004
>= Moderate MR		5848	-	1.08 (0.82, 1.41)	0.596
≥ Moderate AS		5848	<b>+</b>	1.18 (0.86, 1.63)	0.309
RVSP ≥ 35 mmHg		5848	<b></b> ■-	1.57 (1.05, 2.34)	0.026
RAP (mmHg)	RAP < 8 mmHg	3938	÷.	Reference	
	RAP 8-15 mmHg	1691	<b> </b>	1.81 (1.36, 2.40)	<0.001
	RAP ≥ 15 mmHg	219	¦- <b></b> -	1.87 (1.16, 3.02)	0.010
LVEF ≤ 35		5848	+	0.97 (0.69, 1.36)	0.841
			1 2 5 10		

- Progression to severe TR was dependent on the index TR severity (0.3% mild; 1.9% mild-moderate; 4.2% moderate; 10% moderate-severe).
- ► However, when controlling for index TR severity, RVSP, RAP, and age, females had a 1.6x (95% CI HR 1.21-2.09) higher risk of progressing to severe TR.

### Predictors of Follow-up Echo

Has fup Echo: 10696/33108 patients		Odds ratio		р	
TR Severity at index	mild	12870		Reference	
	mild-moderate	1838	+	1.06 (0.95, 1.18)	0.33
	moderate	2196	-	1.10 (0.99, 1.23)	0.07
	moderate-severe	481	+	1.03 (0.84, 1.26)	0.78
Gender	Male	8456	•	Reference	
	Female	8929		0.83 (0.78, 0.89)	<0.001
Patient Admission Status	Outpatient	10038		Reference	
	Inpatient	7347	•	0.94 (0.88, 1.02)	0.12
Age (years)		17385		1.02 (1.01, 1.02)	<0.001
>= Moderate MR		17385		1.30 (1.20, 1.41)	<0.001
≥ Moderate AS		17385	-	2.55 (2.32, 2.82)	<0.001
RVSP ≥ 35 mmHg		17385		1.38 (1.27, 1.50)	<0.001
RAP (mmHg)	RAP < 8 mmHg	12522	ė.	Reference	
	RAP 8-15 mmHg	4309	•	1.01 (0.94, 1.10)	0.75
	RAP ≥ 15 mmHg	554	<b>⊢⊞</b> -∤	0.84 (0.69, 1.02)	0.07
LVEF ≤ 35		17385	-	1.39 (1.24, 1.54)	<0.001
h-			1 1.5 2 2.5		

- When controlling for other variables, an increased severity at index did not result in higher odds of a follow-up echo (moderate-severe vs mild TR, OR=1.03, p=0.78)
- Females were 20% less likely to receive a follow up echo (95% CI OR 0.78-0.89).
- LVEF ≤ 35% (95% CI OR 1.24-1.54), ≥ moderate MR (95% CI OR 1.20-1.54), and ≥ moderate AS (95% CI 2.32-2.52) resulted in higher odds of receiving a follow-up echo.

### Conclusions

- These findings highlight the importance of comprehensive risk assessment.
- These findings raise concerns about under-recognition of the importance of TR follow-up and potential sex disparities in TR management and follow-up.